ArticleCancer management and research2025
Serum tRF5-23-GlyTCC-2 Functions as a Tumor Suppressor and Novel Biomarker for Colorectal Cancer.
Article in Cancer management and research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Transfer RNA-derived small RNAs (tsRNAs) are a recently discovered class of non-coding RNAs with aberrant expression in various cancers. Substantial evidence implicates tsRNAs in the initiation and progression of colorectal cancer (CRC). This study aimed to investigate the diagnostic and prognostic potential of a specific tsRNA, tRF5-23-GlyTCC-2, in CRC. Methods: We identified tRF5-23-GlyTCC-2 via high-throughput RNA sequencing and validated its expression using qRT-PCR. Associations between tRF5-23-GlyTCC-2 expression, clinicopathological features, and patient survival were assessed with Chi-square and Kaplan-Meier analyses. Its diagnostic performance was evaluated by ROC curve analysis. Functional roles in CRC were examined using colony formation assays and xenograft mouse models. Results: Expression of tRF5-23-GlyTCC-2 was significantly downregulated in CRC tissues (P = 0.0009) and serum (P < 0.0001) compared to controls. It effectively discriminated CRC patients from healthy individuals and those with colorectal polyps, and served as a strong predictor of poor prognosis. Low tRF5-23-GlyTCC-2 levels were correlated with advanced invasion, metastasis (P = 0.0153), and poor prognosis (P = 0.004). ROC analysis demonstrated its superior diagnostic accuracy over traditional biomarkers (AUC = 0.8628), and its combination with CEA further improved the diagnostic performance (AUC = 0.9077). Both in vitro colony formation assays and in vivo xenograft models confirmed its tumor-suppressive function by inhibiting tumor growth and progression. Conclusion: Serum tRF5-23-GlyTCC-2 exhibits high diagnostic accuracy, and its combination with CEA achieves superior sensitivity (84%), highlighting its potential as a powerful non-invasive biomarker to improve CRC detection and prognosis prediction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.